We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Kymriah

News List

Novartis could cut its Kymriah price to $160,000 and keep its profit margins fiercepharma
February 12, 2018
Novartis announced a $475,000 sticker price for Kymriah in August, but a new paper claims the price is three times too high. (Novartis)
Novartis' CAR T therapy Kymriah scores accelerated approval in both Europe and US pharmafile
January 18, 2018
Novartis has accepted its proposed label expansion under the accelerated supervision of the two sides of the Atlantic.
Novartis’ Kymriah shows durable response in blood cancer pharmatimes
December 12, 2017
New analysis of trial data on Novartis’ CAR-T therapy Kymriah presented at the 59th American Society of Hematology annual meeting show that the drug sustained complete responses at six months in adults with a difficult to treat form of blood cancer.
Novartis submits second FDA application for CAR-T therapy Kymriah, this time in diffuse large B-cell pharmafile
November 01, 2017
Novartis has submitted a second marketing application for the therapy with the US regulator.

Previous page 1 2 3 4 Next page